Catalyst pharmaceuticals, inc. (CPRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating Activities:
Net income (loss)

10,426

7,929

13,630

10,959

-644

-14,499

-7,838

-5,965

-5,699

-5,387

-4,177

-3,879

-4,967

-4,163

-3,953

-4,568

-5,386

-5,815

-4,449

-4,558

-5,410

-3,490

-5,009

-3,198

-3,811

-1,354

-5,912

-3,143

-1,744

-76

-2,621

-289

-1,089

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation

13

27

6

6

13

12

9

8

8

6

12

12

12

11

9

8

13

6

11

8

8

7

7

6

5

5

5

5

5

2

2

2

2

Amortization of right-of-use asset

62

62

61

60

59

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,519

1,149

817

924

933

1,029

758

791

971

485

529

638

754

488

532

357

457

576

330

363

314

287

444

22

23

42

46

44

41

204

45

45

45

Change in accrued interest and accretion of discount on investments

-81

105

107

23

53

-

-

-

-

0

0

-210

397

-106

106

-152

-733

-389

-521

-333

1,180

-472

906

223

335

-1,330

2,676

498

45

-840

-1,340

776

274

(Increase) decrease in:
Accounts receivable, net

-3,618

441

-281

3,125

7,251

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

254

1,356

329

173

40

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets and deposits

1,711

1,011

1,850

-392

231

832

139

-315

-180

663

-111

-308

-118

737

-340

-372

-480

110

532

-71

-120

235

3,475

-41

-726

620

-125

-128

-66

1,197

-55

-75

43

Increase (decrease) in:
Accounts payable

-2,769

-29

818

388

602

996

418

117

-1,140

863

389

-225

-15

-122

348

-544

-542

977

-499

265

-763

1,289

-713

306

81

-622

1,025

-118

-798

1,009

132

-127

86

Accrued expenses and other liabilities

-3,699

6,139

3,006

4,730

-1,337

5,036

-10

226

-401

664

501

154

-178

217

-660

183

-219

124

317

-63

755

-1,367

4,286

-385

214

-250

348

772

134

-116

-56

-74

-28

Operating lease liability

72

72

69

67

67

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

7,213

12,291

16,262

14,073

-8,016

-8,351

-6,952

-4,761

-6,081

-4,029

-2,632

-3,200

-3,878

-4,411

-3,278

-4,343

-5,930

-4,631

-5,343

-4,245

-3,794

-3,979

-3,552

-2,983

-2,425

-4,130

-1,683

-1,812

-2,249

-1,593

-1,100

-1,144

-1,301

Investing Activities:
Purchases of property and equipment

-

-0

0

13

5

56

23

11

0

-

-

-

-

-

-

-

-

0

14

1

7

13

13

13

17

0

0

-0

9

45

0

1

4

Purchases of investments

-

0

4,952

19,827

9,944

0

0

4,943

31,847

-60

29

1

33

-25

0

28

65

-50

29

-32

34

-5

-28

9,998

-983

6,805

4,195

-1,024

2

-

-

-

-

Proceeds from maturities and sales of investments

5,000

31,658

10,000

9,910

20,400

-

-

-

0

-

-

-

-

568

2,199

949

-0

-0

-0

-0

-0

-0

-0

-0

298

-1

4,987

-997

-1,497

-

-

-

-

Net cash provided by (used in) investing activities

5,000

31,658

5,047

-9,930

10,449

14,143

7,576

-4,955

-31,847

60

-29

-1

-33

586

2,199

832

-65

50

-44

30

-43

-8

15

-10,012

1,265

-6,806

-4,197

2,021

1,485

-14,052

-0

-1

-4

Financing Activities:
Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

34,873

-

-

-

-

-

-

-

0

66

5,559

3,938

0

Payment of employee withholding tax related to stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

11

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Proceeds from issuance of preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Proceeds from issuance of convertible promissory note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

591

113

1,191

1,299

0

0

16

-

-

-

0

-

-

-

-

Proceeds from exercise of stock options

26

578

256

192

89

151

104

8

33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

23

0

-

-

-

-

Net cash provided by (used in) financing activities

26

578

256

192

89

151

104

4

33

-

-

-

-

80

0

0

-11

65

916

113

36,064

1,821

0

26,725

16

189

17,965

23

0

5,082

5,559

3,938

0

Net increase (decrease) in cash and cash equivalents

12,239

44,528

21,565

4,335

2,522

5,943

728

-9,712

-37,896

50,167

-1,254

-1,397

-3,912

-3,745

-1,079

-3,510

-6,007

-4,515

-4,470

-4,101

32,226

-2,166

-3,537

13,729

-1,143

-10,747

12,083

233

-763

-10,563

4,459

2,792

-1,306

Non-cash investing and financing activities:
Unrealized gain (loss) on available-for-sale securities

74

-9

-2

28

13

25

-9

-14

-21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of liability classified warrants for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,059

251

410

0

0

0

18

-

-

-

0

-

-

-

0

Non-cash incentive received from lessor

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Conversion of note to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0